Document Id | 20202201 (2.16.840.1.113883.3.117.1.1.5.2.1.1.2) |
Document Created | July 1, 2015 |
Case | Hemovigilance Module - Monthly Reporting Denominator from July 1, 2015 to July 31, 2015 |
Author | aSoftwareID (2.16.840.1.113883.3.117.1.1.5.2.1.1) |
Document maintained by | 2.16.840.1.114222.4.3.2.11 |
Encounter Location | 2.16.840.1.113883.3.117.1.1.5.1.1 |
Legal authenticator | aLegalAuthenticatorID (2.16.840.1.113883.3.117.1.1.5.1.1.2) signed date/time: July 1, 2008 |
Facility: FACWIDEIN Facility-wide Inpatient (FacWIDEIn) | Reporting Start: July 1, 2015 |
No hemovigilance adverse reactions reported this month | Yes |
No hemovigilance incidents reported this month | No |
Products | Units Transfused | Aliquots Transfused | Total Discards | ||||||
---|---|---|---|---|---|---|---|---|---|
Whole Blood | Total | 100
|
50
|
0 | |||||
Red Blood Cells | Whole Blood Derived | Total | 12 | 24 | 55 | ||||
Not irradiated or leukocyte reduced | 24
|
14
|
4
|
||||||
Irradiated | 0 | 0 | 0 | ||||||
Leukocyte Reduced | 0 | 0 | 0 | ||||||
Irradiated and Leukocyte Reduced | 0 | 0 | 0 | ||||||
Apheresis | Total | 0 | 0 | 0 | |||||
Not irradiated or leukocyte reduced | 0 | 0 | 0 | ||||||
Irradiated | 0 | 0 | 0 | ||||||
Leukocyte Reduced | 0 | 0 | 0 | ||||||
Irradiated and Leukocyte Reduced | 0 | 0 | 0 | ||||||
Platelets | Whole Blood Derived | TOTAL | 0 | 0 | |||||
Not irradiated or leukocyte reduced | 0 | 0 | |||||||
Irradiated | 0 | 0 | |||||||
Leukocyte reduced | 0 | 0 | |||||||
Irradiated and leukocyte reduced | 0 | 0 | |||||||
Apheresis | TOTAL | 0 | 0 | 0 | |||||
Not irradiated or leukocyte reduced | 0 | 0 | 0 | ||||||
Irradiated | 0 | 0 | 0 | ||||||
Leukocyte reduced | 0 | 0 | 0 | ||||||
Irradiated and leukocyte reduced | 0 | 0 | 0 | ||||||
Plasma (all types) | Total | Whole blood Derived | 0 | 0 | 0 | ||||
Total | Apheresis | 0 | 0 | 0 | |||||
Cryoprecipitate | 0 | 0 | |||||||
Red Blood Cells | Whole Blood Derived | TOTAL | 30 | 0 | 0 | ||||
S-303-treated | 30
|
0 | 0 | ||||||
Riboflavin-Treated | 0 | 0 | 0 | ||||||
Apheresis | TOTAL | 0 | 0 | 0 | |||||
S-303-treated | 0 | 0 | 0 | ||||||
Riboflavin-Treated | 0 | 0 | 0 | ||||||
Platelets | Whole Blood Derived | Total | 0 | 0 | |||||
Psoralen-Treated | 0 | 0 | |||||||
Riboflavin-Treated | 0 | 0 | |||||||
Apheresis | Total | 0 | 0 | 0 | |||||
Psoralen-Treated | 0 | 0 | 0 | ||||||
Riboflavin-Treated | 0 | 0 | 0 | ||||||
Plasma (all types) | Whole Blood Derived | Total | 0 | 0 | 0 | ||||
Psoralen-Treated | 0 | 0 | 0 | ||||||
Riboflavin-Treated | 0 | 0 | 0 | ||||||
Apheresis | Total | 0 | 0 | 0 | |||||
Psoralen-Treated | 0 | 0 | 0 | ||||||
Riboflavin-Treated | 0 | 0 | 0 | ||||||
Cryoprecipitate | TOTAL | 0 | 0 | ||||||
Psoralen-Treated | 0 | 0 | |||||||
Riboflavin-Treated | 0 | 0 |
Products | Units Transfused | Aliquots Transfused | Total Discards | |||
---|---|---|---|---|---|---|
Platelets | Apheresis | Psoralen-treated | 0 | 0 | 0 | |
Psoralen-treated and in Plasma | 25
|
75 | 75 | |||
Psoralen-treated and in Platelet additive solution | 75
|
75 | 75 | |||
Riboflavin-treated | 0 | 0 | 0 | |||
Riboflavin-treated and in Plasma | 75 | 75 | 75 | |||
Riboflavin-treated and in Platelet additive solution | 75 | 75 | 75 |
Facility transfuses blood products treated with pathogen reduction technology | Yes |
Number of patient samples collected for type and screen or crossmatch | 25 |
Total crossmatch procedures | 16 |
Total patients transfused | 1024 |